简介：Launched in 2010， the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafenib) study targeted patients with unresectable HCC and who were eligible for systemic therapy， namely with sorafenib. According to one of the lead authors of the study， Dr. Lencioni， “The aim…is to evaluate the safety and efficacy of sorafenib in different subgroups.”